According to Cancer Therapy Advisor, Pazopanib may be associated with response in patients with pancreatic neuroendocrine tumors (PNETs), but not carcinoid tumors. Information about the study was published online in The Lancet Oncology.
Alexandria Phan, MD, and Daniel Halperin, MD, of the MD Anderson Cancer Center, along with other researchers, looked at 52 patients (32 with pancreatic NETs, 20 with carcinoid tumors) from April 2007 to July 2009, who received oral pazopanib daily with octreotide at pre-protocol dosage.
The primary endpoint was the percentage of patients who attained an objective response upon intention-to-treat analysis. They found that seven of the 32 patients with PNETs (21.9 percent) achieved an objective response, while there was no response detected in the first stage of the carcinoid tumor group.
Click here to read the full article.